(PXH) FTSE RAFI Emerging Markets - Overview
Etf: Emerging Markets, Equities, ADRs, GDRs, Large-Cap
Dividends
| Dividend Yield | 4.23% |
| Yield on Cost 5y | 5.82% |
| Yield CAGR 5y | 0.29% |
| Payout Consistency | 92.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 18.3% |
| Relative Tail Risk | -4.67% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.65 |
| Alpha | 26.69 |
| Character TTM | |
|---|---|
| Beta | 0.668 |
| Beta Downside | 0.632 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.72% |
| CAGR/Max DD | 1.15 |
Description: PXH FTSE RAFI Emerging Markets January 15, 2026
The Invesco FTSE RAFI Emerging Markets ETF (NYSE ARCA: PXH) is designed to track the FTSE RAFI Emerging Markets Index, investing at least 90 % of its assets in the index’s constituent securities-including ADRs and GDRs that represent those securities. The index covers roughly 350 large-cap companies located in FTSE-defined emerging-market countries, providing broad exposure to the region’s leading equities.
As of the most recent filing (Q4 2025), PXH holds about $2.1 billion in assets under management with an expense ratio of 0.45 %-both metrics that sit near the median for diversified emerging-market ETFs. The fund’s top sector allocations are financials (≈28 %), technology (≈22 %), and consumer discretionary (≈15 %). Its dividend yield hovers around 2.1 %, and the fund’s performance has historically correlated (≈0.85 R²) with global commodity price movements, reflecting the heavy weighting to resource-rich economies. These drivers suggest that shifts in global growth outlooks, commodity cycles, and emerging-market currency stability will materially affect PXH’s returns.
For a deeper, data-driven look at how PXH’s factor exposures compare to peers, you might explore the analytics on ValueRay.
What is the price of PXH shares?
Over the past week, the price has changed by +1.27%, over one month by +5.63%, over three months by +7.56% and over the past year by +36.05%.
Is PXH a buy, sell or hold?
What are the forecasts/targets for the PXH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 33.6 | 20.4% |
PXH Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.87b USD (1.87b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.87b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.87b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.38% (E(1.87b)/V(1.87b) * Re(8.38%) + (debt-free company))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)